Home / Cancer treatment in China / Colorectal cancer treatment
Access, not a slogan
Colorectal Cancer Treatment in China
Colorectal cancer care in China starts with the same decisions used elsewhere: colon or rectum, stage, whether disease can be removed, and the molecular profile. What can differ in 2026 is access to specific labelled drugs and to CSCO-listed sequences, not a different biology. Trastuzumab rezetecan is a later-line option only for defined HER2-positive disease. Encorafenib plus cetuximab is a post-therapy option for BRAF V600E metastatic disease. A colorectal department is not proof of drug stock, a trial seat, or acceptance of an international file. Cost is a written estimate.
Applicability: pathology, stage, and the molecular report come before a hospital name. A department listing is not a trial seat.
Label is not accessNo package priceScreening is not enrollment
From the report to a center
The sequence is pathology, then stage, then the molecular profile, then the treatment question, then a center whose page actually documents a colorectal service, then the international-patient route, then a written estimate, then a case review. Skipping to a hospital name reverses that order.
The same five facts come before a drug name: colon or rectum, stage, whether the disease can be removed, where any metastases are, and prior treatment. The markers that change drug choice are RAS and NRAS, BRAF, MSI or MMR, and HER2 when that test was done. Other actionable findings are read the same way. Patient fitness still matters. One of those facts is not a plan.
What treatment is standard in China?
The current national specification is the National Health Commission 2025 edition. It frames colorectal care as surgery, drug therapy, radiation, imaging, and pathology, with colon and rectum handled as related but not identical diseases. Standard care is still resection when disease can be removed, chemotherapy when risk or metastases justify it, and radiation much more often for rectal cancer. The 2026 CSCO interpretations add biomarker sequences on top of that frame. They do not replace it.
What genuinely differs in China?
The difference this page can support is regulatory and guideline context, not a claim that Chinese tumors behave differently. Two examples are documented above the hospital list: a 2026 NMPA-reported indication for trastuzumab rezetecan in a defined HER2-positive population, and a 2025 NMPA-reported indication for encorafenib plus cetuximab after prior therapy in BRAF V600E metastatic disease. CSCO 2026 interpretations discuss earlier use of the BRAF combination. A US label and a China label are allowed to differ. Neither label is a bed in a named hospital.
What new colorectal options are reported in China in 2026?
The evidence table, with statuses kept separate, is on new colorectal cancer treatments in 2026. The short version: one new HER2 antibody-drug conjugate indication, a guideline move for a BRAF combination, and an IND for an experimental PD-L1/4-1BB combination. The IND is not an approved cancer treatment.
Which biomarkers should be checked?
RAS and NRAS, BRAF, MSI or MMR, and HER2 when metastatic or later-line choices are on the table. MSI or MMR also matters in some non-metastatic chemotherapy decisions. A missing report is a records problem. It is not a reason to guess the drug. Immunotherapy limits are on the immunotherapy page.
Which hospitals have a documented colorectal service on this site?
| Center | Capability on this site | Access | Remote review | International-patient route | Cost / quote |
|---|---|---|---|---|---|
| Sun Yat-sen University Cancer Center | The ParkMega page lists disease-specific colorectal and gastric surgical teams, with systemic and radiation oncology support. | Not verified for a named colorectal drug, a trial slot, or proton therapy. | Pre-arrival medical-file review is verified on that page. A remote treatment plan is not. The page does not call the review a colorectal protocol review. | The page is an international-patient guide and verifies pre-arrival file review. A guide is not acceptance into a colorectal program. | No colorectal package price. The Sun Yat-sen budget page is a hospital budget, not a CRC quote. |
| Fudan University Shanghai Cancer Center | The ParkMega page lists a large colorectal surgical program and multidisciplinary research, including organ-preservation strategies in selected rectal cancers. | Not verified for a named drug or a trial slot. | Not verified as a colorectal remote-review service. | The page is written for international patients and says access should be verified separately from clinical strength. A page is not acceptance. | No colorectal package price is published here. |
Fuda Cancer Hospital’s page lists colorectal cancer among gastrointestinal diagnoses that may involve surgery, systemic therapy, or radiation. That sentence is not a colorectal department, a named drug program, or trial access, so Fuda is not listed above as a colorectal center. Modern Cancer Hospital Guangzhou’s oncology page does not document a colorectal service. A surgical team, even where one is listed, does not prove trial access, stock of trastuzumab rezetecan or encorafenib, proton eligibility, or acceptance of an international patient.
The directory is hospitals in China. The wider context is cancer treatment in China and new cancer treatments in China.
Can international patients access the relevant department?
Not from this page. The Sun Yat-sen page verifies pre-arrival medical-file review for international patients and does not verify a remote treatment plan. The Fudan page is written for international patients and says access should be verified separately from clinical strength. Neither page states a colorectal protocol review. Sending records is not acceptance.
What determines cost?
There is no single colorectal package price. Cost moves with stage, whether surgery is done, the length of stay, the chemotherapy regimen and the number of cycles, a targeted or immunotherapy drug, biomarker testing, radiotherapy, a local treatment for a metastasis, whether care is inside a trial, and the international-patient service path. A written estimate has to name those items. General cancer costs are explained on cancer treatment cost in China. The Sun Yat-sen budget page is a hospital budget guide, not a colorectal tariff.
What records are needed for case review?
- Pathology, including colon versus rectum
- Stage and the imaging that supports it, especially liver and lung
- Prior operations and prior drug regimens
- RAS, NRAS, BRAF, MSI or MMR, and HER2 if tested
- A current medication list and a statement of fitness for treatment
Do not put those results in a website form. The case-review step asks for records through the existing handoff. Diagnosis, marker values, and contact details are not analytics fields.
In this cluster
- Colorectal cancer treatment
- Treatment by stage
- Metastatic disease
- Immunotherapy
- New treatments in 2026
- Treatment in China (this page)
Technology pages already on this site, used only when a case actually needs them: proton therapy, microwave ablation, cryoablation, and interventional oncology. None of those replaces surgery or systemic therapy for colorectal cancer as a default. A country comparison, without a savings claim, is on cancer treatment in China vs the US.
Questions people ask
How much does colorectal cancer treatment cost in China?
There is no verified single price. Cost depends on stage, surgery, hospital stay, the drug regimen and how many cycles, targeted or immunotherapy drugs, biomarker tests, radiotherapy, local treatment of metastases, trial status, and the international-patient path. The next step is a written estimate for the actual case, not a package.
Which China hospitals treat colorectal cancer?
On this site, Sun Yat-sen University Cancer Center documents colorectal and gastric surgical teams, and Fudan University Shanghai Cancer Center documents a large colorectal surgical program. That is a capability statement, not acceptance, not drug stock, and not a trial seat. Fuda names colorectal cancer inside a gastrointestinal list. That mention is not treated here as a colorectal program.
Can foreign patients receive colorectal cancer treatment in China?
Sometimes a department will review an international file. This site has not verified a standing remote-review or acceptance route for colorectal protocols. A hospital guide is not a booking. Screening is not enrollment.
What new colorectal cancer treatments were introduced in China in 2026?
Trastuzumab rezetecan, for adults with HER2-positive colorectal cancer after oxaliplatin, fluorouracil, and irinotecan have failed. BRAF combinations are partly a 2025 label and partly a 2026 guideline move. An IND is not a 2026 treatment approval.
Sources
- NCI, Colon Cancer Treatment (PDQ) patient version. Used for the general distinction between colon treatment and a personal plan.
- NCI, Rectal Cancer Treatment (PDQ) patient version. Used for the point that rectal cancer more often involves radiation than colon cancer.
- National Health Commission colorectal cancer specification, 2025 edition. English summary: Chin J Cancer Res 2025;37(6):949-961. doi 10.21147/j.issn.1000-9604.2025.06.07. This is a practice framework, not a 2026 drug list.
- CSCO colorectal guideline version 2026, as interpreted in Chin J Cancer Res 2026;38(3):329-335. doi 10.21147/j.issn.1000-9604.2026.03.10. The full guideline PDF was not pasted here.
- Cao and Jiang, 1 October 2026. Digestive Oncology, electronic edition, 2026;18(3):358-363. Used for the metastatic nivolumab sentence, the stage III dMMR adjuvant sentence, and the first-line BRAF move.
- Guangming, 10 August 2026, reporting NMPA wording for adults with HER2-positive colorectal cancer after failure of oxaliplatin, fluorouracil, and irinotecan. HORIZON-CRC01 was reported at ASCO 2026. This is company and news reporting, not an opened NMPA gazette page.
- CancerNetwork, 13 July 2025, reporting NMPA authorization of encorafenib plus cetuximab for adults with previously treated BRAF V600E metastatic colorectal cancer, from a Pierre Fabre release. BREAKWATER: Elez and colleagues, N Engl J Med 2025;392:2425-37. doi 10.1056/NEJMoa2501912.
- BioPharm International, 3 August 2026, reporting the Leads Biolabs announcement that CDE approved an IND for a phase Ib/II trial of opamtistomig plus other drugs in metastatic colorectal cancer. A separate August 2026 NDA acceptance for the same antibody is for extrapulmonary neuroendocrine carcinoma, not colorectal cancer.
Last reviewed: 3 October 2026. A trial permission, a guideline sentence, and a drug label are three different documents.
Check whether this treatment route fits my case
This is a records question, not enrollment and not a promise of acceptance. ParkMega does not choose a drug or reserve a bed.